• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Iterum Therapeutics Announces NDA for Oral Sulopenem americanpharmaceuticalreview
    January 29, 2021
    Iterum Therapeutics announced the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in ...
  • Iterum hit by failure of anti-infective sulopenem pharmatimes
    June 04, 2020
    Shares in Dublin, Ireland and Chicago, US-based Iterum Therapeutics have taken a hit on news that the firm's sulopenem did not achieve statistical non-inferiority relative to ertapenem in a trial in complicated urinary tract infection (cUTI).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service